Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1988-10-18
pubmed:abstractText
The interactions of properdin with both surface-bound and fluid-phase C3 (the third component of complement) and its activation products have been investigated by using a purified preparation of the 'native' form. At physiological ionic strength, a weak interaction with cell-bound C3b (the larger activation fragment of C3) could be demonstrated. In the presence of Factor B this interaction was enhanced, and further enhancement was seen when C3bBb sites were formed on the erythrocytes. The avidities of properdin for cell-bound iC3b (the initial product of Factors I and H action on C3b) and C3b were compared at low ionic strength, with that measured for iC3b being less than that for C3b. In contrast, the affinities of properdin for fluid-phase C3b, iC3b and C3c (the larger product of Factors I and H or CR1 (the C3b receptor) action on iC3b) were all very similar, and apparently much weaker than that for cell-bound C3b. No interaction with either native C3 or, more surprisingly, C3i (haemolytically inactive C3) could be detected. Properdin also inhibited Factor I binding to, and action upon, cell-bound C3b, but did not inhibit Factor I action on fluid-phase C3b. These data permit a more detailed description of the roles of properdin in the alternative pathway of complement activation, emphasizing its importance in concentrating activation at the activating surface.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-1067618, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-1165475, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-1185108, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-13186838, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-180780, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-2419425, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-2647, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-266208, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-276881, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-279011, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-3307764, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-4169693, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-4477550, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-4632688, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-4850305, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-4982185, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-5432063, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-559720, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6161872, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6171865, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6177820, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6199050, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6224880, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6225800, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6238433, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-62817, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-637870, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6457754, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6462133, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6607952, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6696726, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6707020, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6912277, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6928644, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-6978375, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-7103942, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-7284336, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-7341961, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-839069, http://linkedlifedata.com/resource/pubmed/commentcorrection/3421908-978134
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0264-6021
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
252
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
47-54
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
pubmed:affiliation
Mechanisms in Tumour Immunity Unit, MRC Centre, Cambridge, U.K.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't